Discover
IRD
Opus Genetics, Inc.
4.18
2 x 3.04
2 x 5.03
bid
ask
+
0.07
1.70%
2 @ 05:00 AM
4.10 -0.08 (1.91%)
| Ytd | 107.96% | |
| 1y | 344.68% |
3.93
day range
4.24
0.93
52 week range
5.81
| Open | 4.06 | Prev Close | 4.11 | Low | 3.93 | High | 4.24 | Mkt Cap | 345.13M |
| Vol | 804.13K | Avg Vol | 971.34K | EPS | -1.31 | P/E | N/A | Forward P/E | -1.20 |
| Beta | 0.32 | Short Ratio | 4.69 | Inst. Own | 8.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 4.49 | 200-d Avg | 3.27 | 1yr Est | 10.50 |
IRD News
benzinga.com
Opus Genetics Set To Join Russell 3000, 2000, Microcap Indexes, Effective June 29
Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stag
globenewswire.com
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (t
benzinga.com
Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13
Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and rai
benzinga.com
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy
benzinga.com
Citizens Reiterates Market Outperform on Opus Genetics, Maintains $11 Price Target
Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform
benzinga.com
Opus Genetics Files Prospectus For Offering 2.679M Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1228627/000114036126024283/ny20075388x1_s3.htm
benzinga.com
Guggenheim Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $16
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Opus Genetics (NASDAQ:IRD) with a B